Procept Biorobotics Corp income statement

In fiscal 2025, Procept Biorobotics Corp reported revenue of $308m, up 37.2% on the year before, operating income of −$104m (a -33.7% margin) and net income of −$95.6m, or −$1.72 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Procept Biorobotics Corp: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	8	34	75	136	224	308	337
Cost of revenue	9	19	38	65	87	112	121
Gross profit	−1	16	37	71	137	196	217
Research and development	16	19	29	48	62	71	79
Selling, general and administrative	30	51	89	132	171	229	252
Operating income	−48	−54	−81	−109	−97	−104	−114
Interest expense	5	6	5	4	4	4	3
Provision for credit losses	—	—	0	0	1	—	—
Income before tax	—	—	—	−106	−91	−95	—
Income tax	0	0	0	0	0	0	—
Net income	−53	−60	−87	−106	−91	−96	−110
Diluted EPS	−$14.47	−$3.63	−$1.96	−$2.24	−$1.75	−$1.72	−$1.95
Diluted shares (average)	4m	16m	44m	47m	52m	56m	56m
EBITDA	−45	−51	−78	−105	−91	−97	−107

US$ millions unless shown otherwise. Fiscal quarters.

Procept Biorobotics Corp: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	58	68	69	79	83	76	83	94
Cost of revenue	21	25	25	27	29	30	29	32
Gross profit	37	44	44	52	54	46	54	62
Research and development	17	15	16	18	18	19	21	20
Selling, general and administrative	43	48	55	56	59	58	65	70
Operating income	−22	−20	−27	−22	−23	−31	−33	−27
Interest expense	1	1	1	1	1	1	1	1
Provision for credit losses	—	0	—	—	—	—	—	—
Income before tax	—	—	−25	−19	—	—	−32	−27
Income tax	—	—	−0	0	—	—	−0	0
Net income	−21	−19	−25	−20	−21	−30	−32	−27
Diluted EPS	−$0.40	−$0.34	−$0.45	−$0.35	−$0.38	−$0.53	−$0.56	−$0.47
EBITDA	−21	−18	−26	−21	−22	−29	−31	−25

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PRCT vs STAA ANGO vs PRCT INGN vs PRCT

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Procept Biorobotics Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Procept Biorobotics Corp.